HX009
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for HX009, covering 2024-07-22 to 2026-04-20. Get the full timeline:
Most recent: Clinical Trial Update: Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma [Phase 1, Phase 2]